Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Атипичный гемолитико-уремический синдром

Список литературы

  1. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009;361:1676-1687
  2. Campistol JM, Arias M, Ariceta G et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nephrologia 2013;33(1):27-45
  3. Демьянова КА. Роль изменений комплемента в развитии поражения почек у больных с микроангиопатическими синдромами: дис. канд. мед. наук: 14.01.29. - М., 2018. - 152 с
  4. Gavriilaki E, Anagnostopoulos A, Mastellos DC. Complement in thrombotic microangoipathies: unreveling Ariadneʾs thread into labyrinth of complement therapeutics. Front Immunol 2019;10:337. doi: 10.3389/fimmu.2019.00337.
  5. Greenbaum LA. Atypical hemolytic uremic syndrome. Adv Pediatr 2014;61(1):335-356
  6. Dragon-Durey MA, Sethi SK, Bagga A et al. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 2010;21:2180-2187
  7. Fremeaux-Bacchi V, Fakhouri F, Garnier A et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 2013;8(4):554-562
  8. Yoshida Y, Kato H, IkedaY, Nangaku M. Pathogenesis of atypical haemolytic uraemic syndrome. J Atheroscler Thromb 2019;26:99-110. doi: 10.5551/jat.RV17026
  9. Rodriguez de Cordoba S, Hidalgo MS, Pinto S, Tortajada A. Genetics of atypical hemolytic uremic syndrome (aHUS). Semin Thromb Hemost 2014;40:422-430. doi: 10.1055/s-0034-1375296
  10. Jozsi M, Licht C, Strobel S et al. Factor F autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 2008;111:1512-1514
  11. Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 2012;8(11):622-633
  12. Meri S. Complement activation in diseases presenting with thrombotic microangiopathy. Eur J Intern Med 2013;24(6):496-502. doi: 10.1016/j.ejim.2013.05.009
  13. Riedl M, Fakhouri F, Le Quintrec M et al. Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches. Semin Thromb Hemost 2014;40:444-464
  14. Fakhouri F, Zuber J, Fremeaux-Bacchi V, Loirat C. Hemolytic uremic syndrome. Lancet 2017;390:681-696. doi: 10.1016/S0140-6736(17)30062-4
  15. Cataland SR, Wu HM. Diagnosis and management of complement mediated thrombotic microangiopathies. Blood Rev 2014;28(2):67-74
  16. Loirat C, Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011;6:60. doi: 10.1186/1750-1172-6-60
  17. Yan K, Desai K, Gullapalli L et al. Epidemiology of atypical hemolytic uremic syndrome: a systematic literature review. Clinical Epidemiology 2020;12:295-305
  18. Besbas N, Karpman D, Landau, Daniel LC. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura, and related disorders. Europian Paediatric Research Group for HUS. Kidney International 2006;70:423-431
  19. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998;339:1585-1594
  20. Moake J. Thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Best Practice&Research Clinical Haematology 2009;22:567-576
  21. Goodship TH, Cook HT, Fakhouri F et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusion from a “Kidney Disease: improving Global Outcomes” (KDIGO) controversies conference. Kidney Int 2017;91(3):539-551. doi: 10.1016/j.kint.2016.10.005
  22. Kato H, Nangaku M, Okada H, Kagami S. Controversies of the classification of TMA and the terminology of aHUS. Clinical and Experimental Nephrology 2017;22(1). doi: 10.1007/ s10157-017-1524-4
  23. Le Clech A, Simon-Tillaux N, Provot F et al. Atypical and secondary hemolytic uremic syndrome have a distinct presentation and no common genetic risk factors. Kidney Int 2019;95:1443-1452. doi: 10.1016/j.kint2019.01.023
  24. Praga M, Rodriguez de Cordoba S. Secondary atypical hemolytic uremic syndrome in the era of complement blockade. Kidney Int 2019;95:1298-1300. doi: 10.1016/j/kint2019.01.043
  25. Brocklebank V, Wood KM, Kavanagh D. Thrombotic microangiopathy and the кidney. Clin J Am Soc Nephrol 2018;13:300-317. doi: 10.2215/CJN.00620117
  26. Aigner C, Schmidt A, Gaggl M, Sunder-Plassmann G. An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy. Clinical Kidney Journal 2019;12(3):333-337. doi: 10.1093/ckj/sfz040
  27. Sallée M, Ismail K, Fakhouri F et al. Thrombocytopenia is not mandatory to diagnose haemolytic and uremic syndrome. BMC Nephrol 2013;14(3):1-6
  28. Hofer J, Rosales A, Fisher C, Giner T. Extra-renal manifestations of complement- mediated thrombotic microangiopathies. Pediatric Nephrol 2014;2:1-16
  29. Swisher KK, Doan JT, Vesely SK et al. Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a systematic review of published reports. Haematologica 2007;92:936-943
  30. Noris M, Remuzzi G. Cardiovascular complications in atypical haemolytic uraemic syndrome. Nat Rev Nephrol 2014;10(3):174-180
  31. Sallee M, Daniel L, Piercecchi M et al. Myocardial infarction is a complication of factor H associated atypical HUS. Nephrol Dial Transplant 2010;25:2028-2032
  32. Jokiranta S. HUS and atypical HUS. Blood 2017;21(129):2847-2856
  33. Gulleroglu K, Fidan K, Hançer VS et al. Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab. Pediatr Nephrol 2013;28(5):827-30. doi: 10.1007/s00467-013-2416-9
  34. Кучиева АМ, Козловская НЛ, Демьянова КА, Добросмыслов ИА. Рецидивирующий атипичный гемолитико-уремический синдром, манифестировавший поражением поджелудочной железы. Нефрология и диализ 2013;15(3):236-239
  35. Loirat C, Fakhouri F, Ariceta G et al. An international consensus approach to the management of the atypical hemolytic uremic syndrome in chidren. Pediatr Nephrol 2016;31(1):15-39. doi: 10.1007/s00467-015-3076-8
  36. Scully M, Goodship T. How I Treat thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome. Br J Haematol 2014;164(6):759-766. doi: 10.1111/bjh.12718
  37. Azoulay E, Knoeble P, Garnacho-Montero J et al. Expert Statements on the Standard of Care in Critically Ill Adult Patients with Atypical Hemolytic Uremic Syndrome. Chest 2017;152(2):424-434
  38. Shen YM. Clinical evaluation of thrombotic microangiopathy: identification of patients with suspected atypical hemolytic uremic syndrome. Thrombosis Journal 2016;14(suppl 1):19. doi: 10.1186/s12959-016-0114-0
  39. Cheong HI, Jo SK, Yoon SS et al. Clinical practice guidelines for the management of atypical hemolytic uremic syndrome in Korea. J Korean Med Sci 2016;31:1516-1528. doi: 10.3346/jkms.2016.31.10.1516
  40. Taylor CM, Machin S, Wigmore SJ, Goodship THJ. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. BJH 2009;148:37-47
  41. Kato H, Nangaku M, Hataya H et al. Clinical guides for atypical haemolytic uraemic syndrome in Japan. Clin Exp Nephrol 2016;20(4):536-543. doi: 10/1007/s10157-016- 1276-6
  42. Go RS, Winters JL, Leug N et al. Thrombotic microangiopathy care pathway: a consensus statement for the Mayo Clinic complement alternative pathway - thrombotic microangiopathy (CAP-TMA) disease-oriented group. Mayo Clin Proc 2016;91(9):1189- 1211. doi: 10.1016/j.mayocp.2016.05.015
  43. Al-Nouri ZL, Reese JA, Terrell DR et al. Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood 2015;125(4):616-618
  44. Eremina V, Jefferson JA, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008;358:1129-1136
  45. Asif A, Nayer A, Haas CS. Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab. J Nephrol 2017;30(3):347-362. doi: 10.1007/s40620-016- 0357-7
  46. El-Husseini A, Hannan S, Awad A et al. Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab. Am J Kidney Dis 2015;65(1):127-130
  47. Fakhouri F, Roumenina L, Provot F et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol 2010;21:859-867
  48. Zhang B, Xing C, Yu X et al. Renal thrombotic microangiopathies induced by severe hypertension. Hypertens Res 2008;31:479-483
  49. Timmermans SAMEG, Abdul-Hamid MA, Vanderlocht J et al. Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities. Kidney Int 2017;91:1420-1425
  50. Шевченко ЮЛ, Новик АА, Мельниченко ВЯ. Анемии (руководство по диагностике и лечению). М.: РАЕН, 2012. – 350 с. https://akusher-lib.ru/wp- content/uploads/2019/07/Anemii-rukovodstvo-po-diagnostike-i-lecheniyu.pdf
  51. Menne J, Nitschke M, Stingele R et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome:case-control study. BMJ 2012;19;345:e4565. doi: 10.1136/bmj.e4565
  52. Shah N, Rutherford C, Matevosyan K et al. Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP). Br J Haematol 2013;163(4):514-9. doi: 10.1111/bjh.12569
  53. Bendapudi PK, Li A, Hamdan A et al. Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA Research Collaborative. Br J Haematol 2015;171(5):836-44. doi: 10.1111/bjh.13658
  54. Hassan S, Westwood JP, Ellis D et al. The utility of ADAMTS13 in differentiating TTP from other acute thrombotic microangiopathies: results from the UK TTP Registry. Br J Haematol 2015;171(5):830-5. doi: 10.1111/bjh.13654
  55. Coppo P, Schwarzinger M, Buffet M et al. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS One 2010;5(4):e10208
  56. Cataland SR, Yang S, Wu HM. The use of ADAMTS13 activity, platelet count, and serum creatinine to differentiate acquired thrombotic thrombocytopenic purpura from other thrombotic microangiopathies. Br J Haematol 2012;157(4):501-503
  57. Phillips EH, Westwood JP, Brocklebank V et al. The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies. J Thromb Haemost 2016;14(1):175-85. doi: 10.1111/jth.13189
  58. Wada H, Matsumoto T, Suzuki K et al. Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy. Thromb J 2018;16:14. doi: 10.1186/s12959-018-0168-2
  59. Lee H, Kang E, Kang HG et al. Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome. Korean J Intern Med 2020;35(1):25-40. doi: 10.3904/kjim.2019.388
  60. Lupu F, Keshari RS, Lambris JD, Coggeshall KM. Crosstalk between the coagulation and complement systems in sepsis. Thromb Res 2014;133(suppl 1):S28-S31
  61. Noris M, Caprioli J, Bresin E et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010;5(10):1844-1859
  62. Fremeaux-Bacchi V, Fakhouri F, Garnier A et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 2013;8(4):554-62
  63. Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol 2013;33:508-530. doi: 10.1016/j.semnephrol.2013.08.003
  64. Cataland SR, Holers VM, Geyer S et al. Biomarkers of the alternative pathway and terminal complement activity at presentation confirms the clinical diagnosis of aHUS and differentiates aHUS from TTP. Blood 2014;123:3733-3738
  65. Noris M, Galbusera M, Gastoldi S et al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 2014;124:1715-1726
  66. Schaefer F, Ardissino G, Ariceta G et al. Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. Kidney Int 2018;94:408-418. doi: 10.1016/j.kint.2018.02.029
  67. Jiang H, Fan MN, Yang M et al. Association among Complement Factor H Autoantibodies, Deletions of CFHR, and the Risk of Atypical Hemolytic Uremic Syndrome. Int J Environ Res Public Health 2016;13(12):1209. doi: 10.3390/ijerph13121209
  68. KDIGO Clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012;2:1- 138
  69. Campistol JM, Arias M, Ariceta G et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nephrologia 2015;35(5):421-447. doi: 10.1016/j.nefro.2015.07.005
  70. De Serres SA, Isenring P. Athrombocytopenic thrombotic microangiopathy, a condition that could be overlooked based on current diagnostic criteria. Nephrol Dial Transplant 2009;24:1048-1050
  71. Zuber J, Le Quintrec M, Sberro-Soussan R et al. New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol 2011;7(1):23-35. doi: 10.1038/nrneph.2010.155
  72. Caprioli J, Noris M, Brioschi S et al. International Registry of Recurrent and Familial HUS/TTP. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006;108(4):1267-1279. doi: 10.1182/blood-2005-10-007252
  73. Thrombotic microangiopathy: current knowledge and outcomes with plasma exchange. Seminars in Dialysis 2012;25(2):214-219. doi: 10.1111/j.1525-139X.2011.01035x
  74. Fox LC, Cohney SJ, Kausman JY et al. Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand. Nephrology (Carlton) 2018;23(6):507-517. doi: 10.1111/nep.13234
  75. Michael M, Elliott EJ, Craig JC et al. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am J Kidney Dis 2009;53(2):259-72. doi: 10.1053/j.ajkd.2008.07.038
  76. von Baeyer H. Plasmapheresis in thrombotic microangiopathy-associated syndromes: review of outcome data derived from clinical trials and open studies. Ther Apher 2002;6(4):320-8. doi: 10.1046/j.1526-0968.2002.00390.x
  77. Coppo P, Bussel A, Charrier S et al. High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome. Medicine (Baltimore) 2003;82(1):27-38. doi: 10.1097/00005792-200301000-00003
  78. Loirat C, Grnier A, Sellier-Leclerc AL, Kwon T. Plasmatherapy in atypical hemolytic uremic syndrome. Semin Thromb Hemost 2010;36:673-681
  79. Clark WF, Huang SS, Walsh MW et al. Plasmapheresis for the treatment of kidney diseases. Kidney Int 2016;90:974-984. doi: 10.1016/j.kint.2016.06.009
  80. Schwartz J, Padmanabhan A, Aqui N et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the seventh special issue. J Clin Apher 2016;31:149- 162. doi: 10.1002/jca.21470
  81. Claes KJ, Massart A, Collard L et al. Belgian consensus statement on the diagnosis and management of patients with atypical hemolytic uremic syndrome. Acta Clin Belg 2018;73:80-89. doi: 10.1080/17843286.2017.1345185
  82. Cohen JA, Brecher ME, Bandarenko N. Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura. J Clin Apher 1998;13(1):16-19
  83. Zuber J, Fakhouri F, Roumenina LT et al.; French Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012;8:643-657. doi: 10.1038/nrneph.2012.214
  84. Krishnappa V, Gupta M, Elrifai M et al. Atypical Hemolytic Uremic Syndrome: A Meta- Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens. Ther Apher Dial 2018;22(2):178-188. doi: 10.1111/1744- 9987.12641
  85. Kise T, Fukuyama S, Uehara M. Successful Treatment of Anti-Factor H Antibody- Associated Atypical Hemolytic Uremic Syndrome. Indian J Nephrol 2020;30(1):35-38. doi: 10.4103/ ijn.IJN_336_18
  86. Sana G, Dragon-Durey MA, Charbit M et al. Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses. Pediatr Nephrol 2014;29:75-83
  87. Cofiell R, Kukreja A, Bedard K et al. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Вlood 2015;21;125(21):3253-62. doi: 10.1182/blood-2014-09-600411
  88. Legendre CM, Licht C, Muus PL et al. Terminal complement inhibitor Eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013;368:2169-2181. doi: 10.1056/NEJMoa1208981
  89. Licht C, Greenbaum LA, Muus P et al. Efficacy and safety of Eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 2015;87:1061-1073. doi: 10.1038/ki.2014.423
  90. Pugh D, O"Sullivan ED, Duthie FA et al. Interventions for atypical haemolytic uraemic syndrome. Cochrane Database Syst Rev 2021;3(3):CD012862. doi: 10.1002/14651858
  91. Bernuy-Guevara C, Chehade H, Muller YD et al. The Inhibition of Complement System in Formal and Emerging Indications: Results from Parallel One-Stage Pairwise and Network Meta-Analyses of Clinical Trials and Real-Life Data Studies. Biomedicines 2020;8(9):355. doi: 10.3390/biomedicines8090355
  92. Menne J, Delmas Y, Fakhouri F et al. Eculizumab prevents thrombotic microangiopathy in patients with atypical hemolytic uremic syndrome in a long-term observational study. Clin Kidney J 2018;12(2):196-205. doi: 10.1093/ckj/sfy035
  93. Menne J, Delmas Y, Fakhouri F et al. Outcome in patients with atypical hemolytic uremic syndrome treated with Eculizumab in a long-term observational study. BMC Nephrology 2019;20:125-137. doi: 10.1186/s12882-019-1314-1
  94. Walle JV, Delmas Y, Ardissino G et al. Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment. J Nephrol 2017;30(1):127-134. doi: 10.1007/s40620-016-0288-3
  95. Ardissino G, Possenti I, Tel F et al. Discontinuation of Eculizumab treatment in atypical hemolytic uremic syndrome: an update. Am J Kidney Dis 2015;66:172-173
  96. Olson SR, Lu E, Sulpizio E et al. When to stop Eculizumab in complement-mediated microangiopathies. Am J Nephrol 2018;48:96-107. doi: 10.1159/000492033
  97. Хроническая болезнь почек (ХБП). Клинические рекомендации. https://rusnephrology.org/wp-content/uploads/2020/12/CKD_final.pdf
  98. Каабак ММ, Молчанова ЕА, Нестеренко ИВ и др. Резолюция Междисциплинарного совета экспертов. Трансплантация почки у пациентов с атипичным гемолитико- уремическим синдромом: клинические и организационно-методические аспекты ведения пациентов. Нефрология 2018;3:8-14. doi: 10.18565/nephrology.2018.3.8-14
  99. Gonzalez Suarez ML, Thongprayoon C, Mao MA et al. Outcomes of Kidney Transplant Patients with Atypical Hemolytic Uremic Syndrome Treated with Eculizumab: A Systematic Review and Meta-Analysis. J Clin Med 2019;8(7):pii:E919. doi: 10.3390/jcm8070919
  100. Siedlecki AM, Isbel N, Vande Walle J et al.; Global aHUS Registry. Eculizumab use for kidney transplantation patients with a diagnosis of atypical hemolytic uremic syndrome. Kidney Int Rep 2018;4(3):434-446. doi: 10.1016/j.ekir.2018.11.010
  101. Keating GM. Eculizumab: a review of its use in atypical haemolytic uraemic syndrome. Drugs 2013;73(18):2053-66. doi: 10.1007/s40265-013-0147-7
  102. Avery RK, Ljungman P. Prophylactic measures in the solid-organ recipient before transplantation. Clin Infect Dis 2001;33(1):15-21. doi: 10.1086/320899
  103. Danzinger-Isakov L, Kumar D. AST Infectious Diseases Community of Practice Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 2009;9(4):258-262. doi: 10.1111/j.1600-6143.2009.02917.x
  104. Резолюция Междисциплинарного совета экспертов по профилактике тяжелых инфекций у пациентов с генетическими нарушениями регуляции системы комплемента, получающих терапию экулизумабом. Эпидемиология и вакцинопрофилактика 2017;1(92):51-55
  105. Bresin E, Daina E, Noris M et al. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol 2006;1:88-99. doi: 10.2215/CJN.00050505
  106. Keller K, Daniel C, Schöcklmann H et al. Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy. Nephrol Dial Transplant 2006;21:2724-2735. doi: 10.1093/ndt/gfl340
  107. Nava F, Cappelli G, Mori G et al. Everolimus, cyclosporine, and thrombotic microangiopathy: clinical role and preventive tools in renal transplantation. Transplant Proc 2014;46:2263-2268. doi: 10.1016/j.transproceed.2014.07.062
  108. Schwimmer J, Nadasdy TA, Spitalnik PF et al. De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy. Am J Kidney Dis 2003;41:471-479. doi: 10.1053/ajkd.2003.50058
  109. Rolla D, Fontana I, Ravetti JL et al. De novo post-transplant thrombotic microangiopathy localized only to the graft in autosomal dominant polycystic kidney disease with thrombophilia. J Renal Inj Prev 2015;4(4):135-138. doi: 10.12861/jrip.2015.28
  110. Zuber J, Le Quintrec M, Krid S et al.; French Study Group for Atypical HUS. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 2012;12:3337-3354. doi: 10.1111/j.1600-6143.2012.04252.x
  111. Matar D, Naqvi F, Racusen LC et al. Atypical hemolytic uremic syndrome recurrence after kidney transplantation. Transplantation 2014;98(11):1205-1212. doi: 10.1097/TP.0000000000000200
  112. Cugno M, Gualtierotti R, Possenti I et al. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Thromb Haemost 2014;12:1440-1448
  113. Wehling C, Amon O, Bommer M et al. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders. Clin Exp Immunol. 2017 Feb;187(2):304-315. doi: 10.1111/cei.12890
  114. Bruel A, Kavanagh D, Noris M et al. Hemolytic uremic syndrome in pregnancy and postpartum. Clin J Am Soc Nephrol 2017;12(8):1237-1247. doi: 10.2215/CJN.00280117
  115. Gupta M, Burwick RM. Pregnancy-associated atypical hemolytic uremic syndrome. A systematic review. Obstetrics&Gynecology 2020;135:46-58. doi: 10.1097/AOG0000000000003554
  116. Grand"Maison S, Lapinsky S. Insights into pregnancy associated and atypical hemolytic uremic syndrome [published correction appears in Obstet Med 2018;11(4):198]. Obstet Med 2018;11(3):137-140. doi: 10.1177/1753495X18780099
  117. Коротчаева ЮВ, Козловская НЛ, Демьянова КА и соавт. Генетические аспекты акушерского гемолитико-уремического синдрома. Клиническая нефрология 2017;1:12-17
  118. Huerta A, Arjona E, Portoles J et al. A retrospective study of pregnancy- associated atypical hemolytic uremic syndrome. Kidney Int 2018;93(2):450-459. doi: 10.1016/j.kint.2017.06.022
  119. Козловская НЛ, Коротчаева ЮВ, Шифман ЕМ, Кудлай ДА. Акушерский атипичный гемолитико-уремический синдром: виновата беременность или ее осложнения? Вопросы гинекологии, акушерства и перинатологии 2020;19(4):81-91. doi: 10.20953/1726–1678-2020-4-81-91
  120. Кирсанова ТВ, Виноградова МА, Федорова ТА. Имитаторы тяжелой преэклампсии и HELLP-синдрома: различные виды тромботической микроангиопатии, ассоциированной с беременностью. Акушерство и гинекология 2016;12:5-14. doi: 10.18565/aig.2016.12.5-14
  121. Padmanabhan A, Connelly-Smith L, Aqui N et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher 2019;34(3):171-354. doi: 10.1002/jca.21705
  122. Stefanovic V. The Extended Use of Eculizumab in pregnancy and complement activation⁻associated diseases affecting maternal, fetal and neonatal kidneys - the future is now? J Clin Med 2019;8(3):407. doi: 10.3390/jcm8030407
  123. Burlinson CEG, Sirounis D, Wally KR, Chau A. Sepsis in pregnancy and the puerperium. Int J Obstet Anesth 2018;36:96-107. doi: 10.1016/j.ijoa.2018.04.010
  124. 125. Nabhan AF, Allam NE, Hamed Abdel-Aziz Salama M. Routes of administration of antibiotic prophylaxis for preventing infection after caesarean section. Cochrane Database Syst Rev 2016;6:CD011876. doi: 10.1002/14651858.CD011876.pub2
  125. Lionet A, Provôt F, Glowacki F et al. A case of adult atypical haemolytic uraemic syndrome related to anti-factor H autoantibodies successfully treated by plasma exchange, corticosteroids and rituximab. NDT Plus 2009;2(6):458-60. doi: 10.1093/ndtplus/sfp109
  126. Breville G, Zamberg I, Sadallah S et al. Case Report: Severe Complement- Mediated Thrombotic Microangiopathy in IgG4-Related Disease Secondary to Anti- Factor H IgG4 Autoantibodies. Front Immunol 2021;11:604759. doi: 10.3389/fimmu.2020.604759

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*